Is USPH a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for U.S. Physical Therapy (USPH) rests on Hospital affiliations: In February 2026 USPH announced two 10-year alliances. The bear case rests on reimbursement is the largest outside risk. Analysts covering it publish targets from $95.00 to $122.00 against a $95.93 share price on November 20, 2026, so even the professionals disagree by 24% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

USPH key stats

At $95.93 on November 20, 2026, U.S. Physical Therapy (USPH) has a market cap of $1.4B and a dividend yield of 1.92%.

Market cap
$1.4B
P/E (forward)
28.5
Price to book
3.3
Dividend yield
1.92%
Beta
1.13

Market cap, P/E and yield are measured at the $95.93 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with U.S. Physical Therapy (USPH)?

The last two weeks for U.S. Physical Therapy, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.

  • USPH closed at $95.93 on November 20, 2026, down 3.7% over the past five trading days (from $99.60).
  • On November 13, 2026, Barrington Research raised its target to $122.00 from $110.00 (Outperform).

Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

U.S. Physical Therapy, Inc. runs outpatient physical and occupational therapy clinics across the United States, about 799 locations at September 30, 2026, and an industrial injury prevention (IIP) business that sends athletic trainers and ergonomic specialists into employer worksites. Physical therapy produced about $190 million of Q3 2026 revenue and IIP about $33 million. The company's model is unusual: it buys a majority stake in a local practice, often 50% to 70%, and the founding therapists keep the rest and keep running it. That keeps clinicians invested, but it also means a large slice of profit belongs to partners, and the value of their stakes runs through earnings per share. The Q3 2026 report on November 4 was the company's strongest quarter of the year. Revenue rose 13% to about $223 million, patient visits rose 8% to 1.7 million, revenue per visit reached a record $111, and adjusted EBITDA climbed to about $28 million from $24 million. Adjusted EPS was $0.80 against $0.66 a year earlier, even though GAAP showed a loss of $1.04 per share because partner stakes were revalued higher. All 72 clinics under two hospital affiliations, including a 10-year alliance with NYU Langone, were integrated by quarter end and produced about $25 million of revenue. Management reaffirmed 2026 adjusted EBITDA guidance of $102 million to $106 million and kept the quarterly dividend at $0.46. The shares had a rough first half. A weather-hit Q1, with more than 31,000 lost visits, and a Q2 adjusted EPS miss ($0.75 against roughly $0.84 expected) pushed the stock to about $59 in May. It recovered through the summer and then rose from about $85 on November 3 to about $99.50 on November 6, close to its 52-week high of about $101.80, before settling at about $96.16 on November 20. At that price USPH trades around 36x trailing adjusted EPS of about $2.68 and roughly 17x to 20x trailing adjusted EBITDA, depending on whether partner stakes are counted. Barrington raised its price target twice after the report, to $110 from $98 and then to $122, and the mean target across six analysts is about $111.50. Investors are paying for 2027 margin gains from the hospital clinics, and rising self-insured employee health costs are the main thing eating into those gains today.

The bull case: what would have to be true for $122.00

The most optimistic published target on USPH is $122.00, +27.2% from the $95.93 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Hospital affiliations

In February 2026 USPH announced two 10-year alliances. Under the first, 60 clinics run by its Metro subsidiary in New York joined NYU Langone's clinical network; under the second, 10 clinics joined a local hospital system. By Q3 the count was 72 clinics, all integrated, generating about $25 million of revenue in the quarter. Hospital-affiliated clinics typically earn higher rates than independent clinics, and management said it expects that revenue to grow significantly as referrals rise, more clinics are added to existing agreements and new hospital deals close. Earlier in the year management talked about at least $14 million of EBITDA lift in 2027 from the original clinics, which would be meaningful against 2026 guidance of $102 million to $106 million.

2. Visit volume and rate per visit

The core engine is simple: more visits per clinic at a higher price per visit. Q3 2026 brought 1.7 million visits, up 8%, with average daily visits per clinic of 33 against 32 a year earlier, and revenue per visit of $111, up $5. Mature clinics grew revenue 6%, the best rate this year (3.5% in Q2). Medicare is a large payer, and the 2026 physician fee schedule gave therapists a modest increase after several years of cuts; guidance included about $2.5 million from Medicare rate changes. Commercial contract renegotiations and growth in cash-pay programs make up the rest of the rate story.

3. Acquisitions under the partnership model

USPH grows by buying controlling stakes in established practices. In 2026 it bought 50% of an eight-clinic practice in January (about $8 million of annual revenue), 70% of an IIP business in January (about $7 million) and 67% of a 12-clinic practice in July for about $16 million (about $12 million of revenue), roughly $37.6 million in total. A new $450 million credit facility closed in April 2026, with a $175 million term loan and a $275 million revolver due 2031, which funds this pace. Borrowings rose to $247 million at September 30 from $162 million at year end, still modest against about $100 million of annual adjusted EBITDA.

4. Industrial injury prevention and cost control

IIP is the smaller, higher-margin side of the business. Q3 revenue was about $33 million, up 14% (8% excluding the January acquisition), and margin improved to 22% from 20%. Employers pay for on-site trainers to cut workplace injury claims, so the work is less exposed to Medicare and insurers. On costs, the company has partly moved front-desk work to virtual staff and says expense controls put in place during Q3 will help later periods. The open item is the self-insured employee medical plan: higher health benefit costs took about 150 basis points off physical therapy margin in Q3, so adjusted PT margin of about 19% would have been higher without them.

The bear case: what would have to be true for $95.00

The most pessimistic published target is $95.00, -1.0% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks U.S. Physical Therapy is worth if the risks below bite instead of the drivers above.

Reimbursement is the largest outside risk. Medicare cut therapy rates for several years before 2026, and part of the 2026 increase came from a one-year boost set by Congress, so a cut in the 2027 fee schedule would hit revenue per visit directly. Commercial insurers can also push rates down or tighten visit limits. Labor is the second: physical therapists are in short supply, wages keep rising, and the company's self-insured health plan has been running well above last year's costs. The partnership structure adds complexity. Partners hold about $357 million of redeemable stakes that USPH may have to buy back under put rights, and their rising value has pushed GAAP EPS negative in three of the last four quarters (a $1.04 loss in Q3) even as adjusted earnings grew. The hospital affiliations are concentrated, with 60 of the 72 clinics tied to one New York system, and the company lists termination of an affiliation as a risk. Weather and seasonality move results, as the 31,000 lost visits in Q1 showed. The CFO seat turned over this year, with Nchacha Etta (formerly of Omnicell) starting September 1. Finally, after the jump to about $99.50 and a close near $96 on November 20, 2026, the stock trades within about 15% of the mean analyst target of roughly $111.50, so the cushion between price and published expectations is thin.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding USPH already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on USPH

6 analysts cover USPH, with an average target of $111.50 (+16.2% against $95.93) and a split of 6 buy, 1 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the USPH forecast and price target page.

How is USPH valued?

Market cap, P/E and dividend yield at today's price are in the USPH key stats above. The business figures below come from U.S. Physical Therapy's reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$838 million (Q3 2026 ~$223 million, up ~13% year over year)
  • Adjusted EBITDA (TTM): ~$100 million (2026 guidance $102 million to $106 million)

As of November 2026: Figures are approximate and tied to the asOf date; verify live numbers before acting. GAAP earnings are not a useful guide here, because the rising value of partners' stakes is charged against EPS without touching cash, which is why the company and analysts lean on adjusted EPS and EBITDA. Even on those measures the stock is not cheap after rising about 17% in three sessions after the report and holding most of that gain. Published analyst targets moved up after the quarter, with Barrington at $122, and the mean of about $111.50 across six analysts sits roughly 16% above the November 20 close.

How do you decide if USPH is a buy?

Whether USPH is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold USPH indirectly through an index or sector ETF before adding more.

What would change your mind on USPH

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Hospital affiliations stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: reimbursement is the largest outside risk fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the USPH stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about USPH against your real portfolio and see your actual exposure before deciding.

Your questions about U.S. Physical Therapy

Ask Walnut's AI anything about USPH and see how it fits what you own.

FAQ

Is USPH a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Hospital affiliations, with revenue (ttm) at ~$838 million (Q3 2026 ~$223 million, up ~13% year over year). The bear case rests on reimbursement is the largest outside risk. Analysts covering it are spread from $95.00 to $122.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell USPH?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Reimbursement is the largest outside risk. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $95.00, -1.0% from the $95.93 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for USPH?

+

Hospital affiliations. In February 2026 USPH announced two 10-year alliances. The most optimistic analyst target on USPH is $122.00, +27.2% from the $95.93 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for USPH?

+

Reimbursement is the largest outside risk. Medicare cut therapy rates for several years before 2026, and part of the 2026 increase came from a one-year boost set by Congress, so a cut in the 2027 fee schedule would hit revenue per visit directly. Commercial insurers can also push rates down or tighten visit limits. Labor is the second: physical therapists are in short supply, wages keep rising, and the company's self-insured health plan has been running well above last year's costs. The partnership structure adds complexity. Partners hold about $357 million of redeemable stakes that USPH may have to buy back under put rights, and their rising value has pushed GAAP EPS negative in three of the last four quarters (a $1.04 loss in Q3) even as adjusted earnings grew. The hospital affiliations are concentrated, with 60 of the 72 clinics tied to one New York system, and the company lists termination of an affiliation as a risk. Weather and seasonality move results, as the 31,000 lost visits in Q1 showed. The CFO seat turned over this year, with Nchacha Etta (formerly of Omnicell) starting September 1. Finally, after the jump to about $99.50 and a close near $96 on November 20, 2026, the stock trades within about 15% of the mean analyst target of roughly $111.50, so the cushion between price and published expectations is thin. The most pessimistic published target is $95.00, -1.0% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does U.S. Physical Therapy do?

+

Operator of outpatient physical therapy clinics and industrial injury-prevention services across the US.

What would have to change for USPH to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Hospital affiliations) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (reimbursement is the largest outside risk) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Is USPH stock worth owning right now?

+

That depends on how much you believe in the hospital affiliation story and what you are willing to pay for it. The business is steady: visits grew 8% in Q3 2026, revenue per visit hit a record $111, and adjusted EBITDA rose to about $28 million. Management reaffirmed 2026 adjusted EBITDA guidance of $102 million to $106 million. Against that, the stock rose from about $85 to about $99.50 in the three sessions after earnings, closed near $96.16 on November 20, 2026, and trades around 36x trailing adjusted EPS, below a mean analyst target of about $111.50 that rose after the report. Someone holding it already might weigh how large the position is relative to a portfolio, since this is a single small-cap healthcare name. Walnut is not an investment adviser, and this is not a recommendation.

What does U.S. Physical Therapy actually do?

+

It owns and manages outpatient physical and occupational therapy clinics, about 799 of them at September 30, 2026, treating patients recovering from surgery, sports injuries, back and joint pain, and workplace injuries. It also runs an industrial injury prevention business that places athletic trainers and ergonomic specialists at employer sites, which brought in about $33 million in Q3. Most clinics are run as partnerships: USPH buys a majority stake in a local practice and the founding therapists keep a minority stake and keep managing it. That approach keeps local leadership in place and gives therapists a share of the profits, which helps with retention in a field where therapists are hard to hire and harder to keep.

Why does USPH report a GAAP loss when adjusted earnings are growing?

+

It comes from the partnership structure. Partners in many clinics hold redeemable stakes that USPH may be required to buy later, and those stakes are carried on the balance sheet at about $357 million. When clinics perform better, the stakes become more valuable. Under GAAP that increase is excluded from net income but deducted in the earnings per share calculation. So in Q3 2026, USPH earned about $11 million in net income attributable to shareholders, yet reported a loss of $1.04 per share. Adjusted EPS, which removes that revaluation and other non-cash items like earnout changes, was $0.80. Analysts mostly use the adjusted figure, but the stakes are a real future claim on cash.

Walnut is informational, not investment advice, and gives no verdict on USPH. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks